Skip to main content

Table 1 Estimated target population

From: Clinical and economic impact of ‘ROS1-testing’ strategy compared to a ‘no-ROS1-testing’ strategy in advanced NSCLC in Spain

  

%

Referencia

n

1

Patients with lung cancer in 2020

[26]

29,188

2

Patients with NSCLC

85.0%

[14]

24,810

3

Patients with stage IV NSCLC with sample available

54.5%

[27]

13,521

4

Patients with stage IV NSCLC non-squamous subtype

66.9%

[16]

9046

5

Patients with stage IV NSCLC squamous subtype

33.1%

[16]

4476

6

Patients with stage IV NSCLC squamous subtype, never smokers

11.9%

[28]

533

7

Candidate for molecular diagnosis (steps 4 + 6)

9579

8

Patients finally tested for EGFR (testing rate)

91.4%

[15]

8755

  1. NSCLC Non-small cell lung cancer, EGFR Epidermal growth factor receptor